Natera, Inc. (NASDAQ:NTRA) CFO Sells $162,693.08 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 946 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $171.98, for a total value of $162,693.08. Following the completion of the sale, the chief financial officer now owns 109,474 shares in the company, valued at approximately $18,827,338.52. The trade was a 0.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 22nd, Michael Burkes Brophy sold 25,931 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $4,277,837.07.
• On Thursday, October 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $126.45, for a total value of $235,955.70.
• On Monday, October 28th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $118.21, for a total transaction of $146,343.98.

Natera Trading Down 2.5 %

Shares of Natera stock opened at $167.61 on Friday. The firm has a market cap of $22.13 billion, a price-to-earnings ratio of -95.23 and a beta of 1.65. Natera, Inc. has a 52-week low of $62.96 and a 52-week high of $183.00. The company’s 50-day simple moving average is $166.20 and its 200-day simple moving average is $136.25. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. During the same period in the prior year, the company posted ($0.95) EPS. The business’s revenue for the quarter was up 63.9% on a year-over-year basis. As a group, equities research analysts anticipate that Natera, Inc. will post -1.56 earnings per share for the current year.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP increased its position in shares of Natera by 205.4% in the third quarter. Wellington Management Group LLP now owns 2,800,263 shares of the medical research company’s stock valued at $355,493,000 after buying an additional 1,883,481 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in Natera by 3.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,482,818 shares of the medical research company’s stock valued at $315,194,000 after acquiring an additional 85,236 shares during the last quarter. Geode Capital Management LLC increased its holdings in Natera by 7.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,090,480 shares of the medical research company’s stock valued at $265,747,000 after acquiring an additional 143,825 shares in the last quarter. Duquesne Family Office LLC raised its position in Natera by 2.4% during the second quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock worth $213,860,000 after acquiring an additional 45,500 shares during the last quarter. Finally, Maverick Capital Ltd. raised its position in shares of Natera by 25.2% during the 3rd quarter. Maverick Capital Ltd. now owns 1,340,045 shares of the medical research company’s stock worth $170,119,000 after purchasing an additional 269,706 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on NTRA. TD Cowen increased their price objective on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Guggenheim upped their target price on shares of Natera from $170.00 to $200.00 and gave the company a “buy” rating in a report on Friday, January 17th. Canaccord Genuity Group upped their price objective on shares of Natera from $165.00 to $180.00 and gave the company a “buy” rating in a research note on Friday, January 3rd. Sanford C. Bernstein lifted their target price on Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Friday, January 10th. Finally, Piper Sandler upped their target price on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a research report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $162.94.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.